EHA 2025: Abstracts Highlight Improving Profiles of Olverembatinib and Lisaftoclax

Research evidence excerpt

EHA 2025: Abstracts Highlight Improving Profiles of Olverembatinib and Lisaftoclax

May 13, 2026 Ascentage Pharma

(AAPG, Buy, $48 PT)

Jeet Mukherjee, Ph.D

EHA 2025: Abstracts Highlight Improving Profiles of Olverembatinib and (332) 400-5178 jmukherjee@btig.com

Lisaftoclax Blake Gitler

(212) 527-3540 bgitler@btig.com

WHAT YOU SHOULD KNOW: AAPG will have a major presence at EHA this year, with Company DataBIOTECHNOLOGY 17 clinical advances, including 8 poster presentations. We highlight takeaways from Closing Price $21.66

select key abstracts below. Overall, the new data are incrementally positive updates

Price Target $48.00 for both olverembatinib and lisaftoclax in CML and Ph+ ALL as we look towards key ph

3 data for both assets in 2027. Market Cap (M) $2,032.52

Shares Out (M) 93.84EQUITY ■ Olverembatinib 2L CML Data Continues to Show Deepening of Responses: The

Avg Daily Vol-3 Months (M) 0.0 data update for the ph 2 single-arm, open-label study evaluating olverembatinib

in 2L CP-CML resistant/intolerant to first-line TKIs w/o the T315I mutation, was Revisions

as of a Jan 14 '26 data cut off vs. a July 24 '25 data cut previously. 75% of pts Previous Current

received 2nd gen TKIs as first line therapy. Among 42 evaluable pts (39 previously) Rating Buy Buy

a 76% CCyR and 48% MMR was achieved, a slight improvement vs. 72% and 44%, Price Target $48.00 $48.00RESEARCH respectively, at the last data cut. Among pts (n=32) treated with a 2nd gen TKI

FY25E REV 82.10 82.10 frontline, 81% achieved CCyR (77% previously) and 50% MMR (43% previously).

cHR and mCR rates were both 83% and in-line with the prior update. On safety, 30% FY26E REV 114.40 114.40

discontinued treatment, mostly due to treatment failure or disease progression. FY27E REV 151.00 151.00